Acute migraine attack (adult)
Adult 18 years or over with a headache like their usual migraine. Screen for red flags (next step) before any treatment.
Acute Migraine Management: Acute migraine attack (adult) → Any red flag for a secondary headache? → Red flag present: urgent assessment, not migraine tr...
Pathway Overview
18 steps
18 total
Adult 18 years or over with a headache like their usual migraine. Screen for red flags (next step) before any treatment.
Yes if any: thunderclap onset, fever or neck stiffness, new deficit or atypical aura, new headache at 50 or over, pregnant or postpartum, immunosuppression or cancer, head injury or anticoagulant, attack over 72 h, or a change from the usual pattern. Yes: urgent assessment first.
Emergency department. Suspected meningitis or giant cell arteritis: treat first, do not wait for CT or LP.
Use the migraine steps only when serious causes are excluded and the headache is the usual migraine.
These change the drug choice.
If any apply, do not use that drug; choose another. Cardiovascular risk factors (for example diabetes, smoking, hypertension, high cholesterol, man over 40): exclude coronary disease before a first triptan. Over 65: sumatriptan not recommended. SSRI or SNRI: watch for serotonin syndrome. Antiemetics: avoid in Parkinson's disease; metoclopramide not with epilepsy or GI bleeding or obstruction.
No: oral treatment. Yes: parenteral treatment in the emergency department. Outside ED, if oral drugs are not tolerated: sumatriptan nasal spray or 6 mg SC, or prochlorperazine 12.5 mg IM, before ED referral.
Adult doses. Give one antiemetic, not both. Parkinson's disease: avoid both. Do not give opioids.
Yes: discharge with a plan. No: reassess for a secondary cause.
Next attack: treat early with what worked. Before ED discharge: return if the headache changes, or with new neurological symptoms or fever.
Pregnant or planning pregnancy: seek specialist advice before any preventive.
Propranolol: not with asthma, bradycardia, heart block or heart failure. Doses: see Therapeutic Guidelines or product information.
GP review of attack frequency, acute drug use and prevention.
Recheck for a secondary cause before more treatment. Do not give opioids.
Neurology-guided treatment after secondary causes are excluded.
Adult doses. Treat early in the attack. Add an antiemetic, even without nausea. Do not use opioids.
Yes: plan for the next attack. No: escalate.
Recheck red flags if the attack is unusual. Do not use opioids.
NICE CG150 Headaches in over 12s: diagnosis and management (last updated June 2025)
Clinical Decision Support — Not a Substitute for Clinical Judgment
Individual patient factors may require deviation from these recommendations.
Known Limitations
Contraindicated Populations
Applicable Regions
AU: Therapeutic Guidelines: Neurology is the local reference. On the ARTG: sumatriptan tablets, nasal spray and 6 mg injection; rizatriptan; eletriptan; rimegepant 75 mg ODT; prochlorperazine 12.5 mg/1 mL injection (IM route in the PI); ketorolac injection (IM route in the PI). Not on the ARTG: dihydroergotamine, lasmiditan, ubrogepant. PBS criteria apply to CGRP-targeting drugs.
UK: NICE CG150 (updated 2025); NICE TA919 (rimegepant) and TA1172 (atogepant) set gepant criteria.
US: AHS 2021 consensus statement (Ailani, doi 10.1111/head.14153), AHS 2016 ED parenteral therapy assessment (Orr, doi 10.1111/head.12835) and ACP 2025 outpatient guideline. Lasmiditan, ubrogepant and dihydroergotamine are available in the US but are not covered here.
Finish the workflow by opening the most relevant calculator, then convert the session into a live account when you are ready.
The Acute Migraine Management is a management clinical algorithm for Neurology. It provides a structured decision tree to guide clinical decision-making, based on NICE CG150 Headaches in over 12s: diagnosis and management (last updated June 2025).
This algorithm is based on NICE CG150 Headaches in over 12s: diagnosis and management (last updated June 2025).
Known limitations include: Adults only; pregnancy needs obstetric or specialist advice beyond the first-line cautions given.; Prevention and medication overuse headache are outlined only; see a prevention pathway and Therapeutic Guidelines: Neurology.; Drug choices and doses follow Australian product information; availability differs by country (for example no dihydroergotamine, lasmiditan or ubrogepant in Australia).; The red-flag screen supports, and does not replace, clinical judgement and local imaging pathways.. Individual patient factors may require deviation from these recommendations.
In AttendMe.ai, the Acute Migraine Management appears automatically when your clinical question matches — alongside evidence from 3M+ peer-reviewed articles.
Try AttendMe Free